Strong interest in PExA’s technology at the international ERS respiratory congress in Barcelona
When PExA participated in the ERS respiratory congress in Barcelona in early September, the company’s booth attracted many visitors and strong interest in PExA’s technology. The company had the opportunity to present the broad potential of the technology for healthcare, research and the pharmaceutical industry within respiratory disease.
PExA participated with its own booth, where the company was represented by CEO Tomas Gustafsson, CTO Svante Höjer and CSO Jörgen Östling. Also attending the congress were the company’s founder, Anna-Carin Olin, from Occupational and Environmental Medicine at Sahlgrenska Academy/Sahlgrenska University Hospital, and the company’s scientific advisor Åsa Wheelock, senior researcher and Associate Professor at Karolinska Institutet.
At the PExA booth, visitors were introduced to the latest developments and opportunities for the company’s technology within biomarker research, PK (pharmacokinetics), PD (pharmacodynamics) and future diagnostics. Small Airway Atlas™, PExA’s knowledge platform for molecular findings from the small airways, was also presented.
“We had many visitors to our booth and strong interest from both new and existing collaborators and customers. The potential applications of our technology within respiratory disease are very broad, which was reflected in the visitors we met, representing areas ranging from lung cancer, COPD, asthma and pulmonary fibrosis to paediatric lung disease. We had extensive discussions with representatives from healthcare, academia and the pharmaceutical industry from around 20 countries worldwide,” says Tomas Gustafsson, CEO of PExA.
In connection with the congress, three accepted abstracts were presented based on research carried out at hospitals and institutes in Sweden, the Netherlands and Germany using PExA’s technology. The studies were based on PExA’s non-invasive method for collecting biomarkers from the small airways and covered areas including pulmonary fibrosis and COPD, chronic obstructive pulmonary disease.
ERS, the European Respiratory Society, is Europe’s largest scientific and clinical organisation in the field of respiratory disease. Its members include researchers, clinicians and healthcare professionals from around the world. ERS annually organises one of the world’s largest congresses in its field, attracting a large number of participants from across the globe. This year’s congress took place in Barcelona from 5 to 9 September.
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 60 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.